<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02881346</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-ENSTILAR-1295</org_study_id>
    <nct_id>NCT02881346</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Enstilar® in Daily Practice</brief_title>
  <official_title>Prospective, Observational, Non-interventional, Multicenter Study on the Efficacy and Tolerability of Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients With Plaque Psoriasis Under Daily Practice Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess how the Enstilar® aerosol foam performs in daily real-life practice
      with regards to effectiveness and convenience of application to psoriasis plaques on body and
      extremities. In addition the profiles of patients prescribed Enstilar® will be described, and
      preceeding, concomitant and follow-up management will be mapped. The study will be conducted
      in about 100 dermatology clinics all over Germany,
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment</measure>
    <time_frame>Week 4</time_frame>
    <description>5-point Likert scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of total body surface area affected</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of related adverse events (ADR)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proportion of patients with no ADRs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment</measure>
    <time_frame>4 weeks</time_frame>
    <description>5-point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI 50</measure>
    <time_frame>4 weeks</time_frame>
    <description>Psoriasis Area and Severity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI 75</measure>
    <time_frame>4 weeks</time_frame>
    <description>Psoriasis Area and Severity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported itching</measure>
    <time_frame>4 weeks</time_frame>
    <description>10-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported sleep loss</measure>
    <time_frame>4 weeks</time_frame>
    <description>10-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported erythema</measure>
    <time_frame>4 weeks</time_frame>
    <description>10-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported scaling</measure>
    <time_frame>4 weeks</time_frame>
    <description>10-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported dry skin</measure>
    <time_frame>4 weeks</time_frame>
    <description>10-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported overall treatment satisfaction</measure>
    <time_frame>4 weeks</time_frame>
    <description>4-point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported satisfaction with effectiveness</measure>
    <time_frame>4 weeks</time_frame>
    <description>4-point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported satisfaction with tolerability</measure>
    <time_frame>4 weeks</time_frame>
    <description>4-point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported satisfaction with convenience</measure>
    <time_frame>4 weeks</time_frame>
    <description>4-point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index</measure>
    <time_frame>4 weeks</time_frame>
    <description>Standard Quality of Life Questionnaire (DLQI)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">410</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Enstilar®</arm_group_label>
    <description>Patients with psoriasis vulgaris plaques on body and/or extremities will apply Enstilar® (calcipotriol /betamethasone dipropionate (50 micrograms/g + 0.5 mg/g) cutaneous foam) once daily for up to 4 weeks, according to the approved labelling of Enstilar® in Germany.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enstilar®</intervention_name>
    <description>Once daily application of cutaneous foam to plaques on body and/or extremities</description>
    <arm_group_label>Enstilar®</arm_group_label>
    <other_name>calcipotriol/betamethasone dipropionate cutaneous foam</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with psoriasis vulgaris plaques on trunk and/or extremities of at least mild
        severity for whom topical treatment with Enstilar® is planned
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age

          -  Psoriasis vulgaris

          -  Lesions on trunk and/or extremities of at least mild severity

          -  Treatment with Enstilar® planned

          -  Signed informed consent to participate

        Exclusion Criteria:

          -  Enrolled in any interventional clinical trial

          -  Ongoing or recent treatment with any systemic psoriasis

          -  Ongoing or recent treatment with UV-therapy

          -  Ongoing or previous treatment with Enstilar®

          -  Psoriasis of scalp only

          -  Other forms of psoriasis, e.g. erythrodermic or pustular psoriasis

          -  More than 30% of surface area affected by psoriasis

          -  Any contraindications or known allergies to Enstilar® or its ingredients

          -  Incapacitated patients under institutionalized care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sascha Gerdes, Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for Dermatology, Venereology and Allergy, University Clinic Schleswig-Holstein, Campus Kiel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic for Dermatology, Venereology and Allergy, University Clinic Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015 Feb;26(1):23-31. doi: 10.3109/09546634.2013.865009. Epub 2013 Dec 20. Review.</citation>
    <PMID>24354461</PMID>
  </results_reference>
  <results_reference>
    <citation>Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6.</citation>
    <PMID>8033378</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2016</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis vulgaris</keyword>
  <keyword>Plaque</keyword>
  <keyword>Topical</keyword>
  <keyword>Calcipotriol</keyword>
  <keyword>Foam</keyword>
  <keyword>Spray</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

